Skip to content

Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers

Jennifer L. Kruse, Megha M. Vasavada, Richard Olmstead, Gerhard Hellemann, Benjamin Wade, Elizabeth C. Breen, John O. Brooks, Eliza Congdon, Randall Espinoza, Katherine L. Narr, Michael R. Irwin

Translational Psychiatry March 21, 2021 DOI: 10.1038/s41398-021-01268-z via DOAJ

Summary

AI-generated from the abstract

Lower baseline levels of the inflammatory marker interleukin-8 (IL-8) in females, but not males, trended toward predicting a better response to ketamine for depression. In 46 depressed patients receiving a single ketamine infusion, changes in IL-8 over time also differed by sex and treatment response: increasing IL-8 was associated with decreasing depression scores in females, while the opposite pattern appeared in males. Other inflammatory markers showed no significant relationships. These preliminary findings suggest that sex differences in IL-8 may help explain how ketamine works and could guide personalized depression treatment.

Study at a glance

Characteristics Open-label trial Peer reviewed
Sample size 46
Population Depressed patients
Intervention Ketamine
Dose 0.5 mg/kg over 40 min
Citations 47
Registration NCT02165449
Key finding Lower baseline IL-8 in females trended with better response to ketamine, and changes in IL-8 over time predicted depression improvement in opposite directions for females and males.

Abstract

Abstract Inflammation plays a role in depression pathophysiology and treatment response, with effects varying by sex and therapeutic modality. Lower levels of interleukin(IL)-8 predict depression response to antidepressant medication and to electroconvulsive therapy (ECT), although ECT effects are specific to females. Whether IL-8 predicts depression response to ketamine and in a sex-specific manner is not known. Here, depressed patients (n = 46; female, n = 17) received open label infusion of ketamine (0.5 mg/kg over 40 min; NCT02165449). Plasma levels of IL-8 were evaluated at baseline and post-treatment. Baseline levels of IL-8 had a trending association with response to ketamine, depending upon sex (responder status × sex interaction: p = 0.096), in which lower baseline levels of IL-8 in females (p = 0.095) but not males (p = 0.96) trended with treatment response. Change in levels of IL-8 from baseline to post-treatment differed significantly by responder status (defined as ≥50% reduction in Hamilton Depression Rating Scale [HAM-D] Score), depending upon sex (responder status × sex × time interaction: F(1,42)=6.68, p = 0.01). In addition, change in IL-8 interacted with sex to predict change in HAM-D score (β = -0.63, p = 0.003); increasing IL-8 was associated with decreasing HAM-D score in females (p = 0.08) whereas the inverse was found in males (p = 0.02). Other inflammatory markers (IL-6, IL-10, tumor necrosis factor-α, C-reactive protein) were explored with no significant relationships identified. Given these preliminary findings, further evaluation of sex differences in the relationship between IL-8 and treatment response is warranted to elucidate mechanisms of response and aid in the development of personalized approaches to depression treatment.

Comments

No comments yet.

Log in to comment